Awards as PI
| Funding | ||
|---|---|---|
| Disease Team Therapy Planning I | Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure | $108,895 |
| Disease Team Planning | {REDACTED} Cardiovascular Regenerative Team | $55,000 |
Total: $163,895.00 |
Awards as Co-PI
| Early Translational III | Heart Repair with Human Tissue Engineered Myocardium |
